Literature DB >> 28971328

Tivozanib: First Global Approval.

Esther S Kim1.   

Abstract

Tivozanib (Fotivda®) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC. Tivozanib is at various stages of development in other countries for advanced RCC and advanced solid tumours. This article summarizes the milestones in the development of tivozanib leading to this first global approval in Europe for the treatment of adults with advanced RCC.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28971328     DOI： 10.1007/s40265-017-0825-y

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  5 in total

1.  Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

Authors:  Robert J Motzer; Dmitry Nosov; Timothy Eisen; Igor Bondarenko; Vladimir Lesovoy; Oleg Lipatov; Piotr Tomczak; Oleksiy Lyulko; Anna Alyasova; Mihai Harza; Mikhail Kogan; Boris Y Alekseev; Cora N Sternberg; Cezary Szczylik; David Cella; Cristina Ivanescu; Andrew Krivoshik; Andrew Strahs; Brooke Esteves; Anna Berkenblit; Thomas E Hutson
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

Review 2.  Tivozanib: status of development.

Authors:  Muhammad Omer Jamil; Amanda Hathaway; Amitkumar Mehta
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

3.  Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.

Authors:  Ferry A L M Eskens; Maja J A de Jonge; Pankaj Bhargava; Toshiyuki Isoe; Monette M Cotreau; Brooke Esteves; Kunihiko Hayashi; Herman Burger; Maarten Thomeer; Leni van Doorn; Jaap Verweij
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

4.  Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.

Authors:  Dmitry A Nosov; Brooke Esteves; Oleg N Lipatov; Alexei A Lyulko; A A Anischenko; Raju T Chacko; Dinesh C Doval; Andrew Strahs; William J Slichenmyer; Pankaj Bhargava
Journal:  J Clin Oncol       Date:  2012-04-09       Impact factor: 44.544

Review 5.  Optimal management of metastatic renal cell carcinoma: current status.

Authors:  Bernard Escudier; Laurence Albiges; Guru Sonpavde
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546
  5 in total
  10 in total

Review 1.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

Review 2.  A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

Authors:  Gizem Kayki-Mutlu; Zinnet Sevval Aksoyalp; Leszek Wojnowski; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-11       Impact factor: 3.195

Review 3.  Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.

Authors:  Kevin Zarrabi; Shenhong Wu
Journal:  Curr Oncol Rep       Date:  2018-04-02       Impact factor: 5.075

4.  Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy.

Authors:  Naveen Kumar; Masoom Raza; Seema Sehrawat
Journal:  Mol Cell Biochem       Date:  2021-07-29       Impact factor: 3.396

Review 5.  Phage Display Technology as a Powerful Platform for Antibody Drug Discovery.

Authors:  Kazuya Nagano; Yasuo Tsutsumi
Journal:  Viruses       Date:  2021-01-25       Impact factor: 5.048

Review 6.  FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.

Authors:  Aleksandra Sochacka-Ćwikła; Marcin Mączyński; Andrzej Regiec
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

7.  Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.

Authors:  Andliena Tahiri; Katarina Puco; Faris Naji; Vessela N Kristensen; Glenny Cecilie Alfsen; Lorant Farkas; Frode S Nilsen; Stig Müller; Jan Oldenburg; Jürgen Geisler
Journal:  Oncotarget       Date:  2022-08-04

Review 8.  Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs.

Authors:  Hussein Sabit; Mohamed Abdel-Hakeem; Tahsin Shoala; Shaimaa Abdel-Ghany; Mokhtar Mamdouh Abdel-Latif; Jawaher Almulhim; Mohamed Mansy
Journal:  Pharmaceutics       Date:  2022-07-28       Impact factor: 6.525

Review 9.  Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors:  Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

10.  Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.

Authors:  Suayib Yalcin; Sahin Lacin
Journal:  Cancer Manag Res       Date:  2019-08-16       Impact factor: 3.989
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.